Selected research
Industry Growth & Trends
Global Age-Related Macular Degeneration (AMD) Therapeutics Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Age-Related Macular Degeneration (AMD) Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Age-Related Macular Degeneration (AMD) Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Age-Related Macular Degeneration (AMD) Therapeutics market include Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd. and Bausch Health Companies, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Age-Related Macular Degeneration (AMD) Therapeutics market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Age-Related Macular Degeneration (AMD) Therapeutics market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Age-Related Macular Degeneration (AMD) Therapeutics market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Age-Related Macular Degeneration (AMD) Therapeutics.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Age-Related Macular Degeneration (AMD) Therapeutics market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Age-Related Macular Degeneration (AMD) Therapeutics Market by Company
Novartis AG
Amgen Inc.
Regeneron Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
Bausch Health Companies, Inc.
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Type
Wet AMD
Dry AMD
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Application
Clinic
Hospital
Research Institute
Other
Age-Related Macular Degeneration (AMD) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age-Related Macular Degeneration (AMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age-Related Macular Degeneration (AMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age-Related Macular Degeneration (AMD) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Age-Related Macular Degeneration (AMD) Therapeutics companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Wet AMD
- Dry AMD
Applications
- Clinic
- Hospital
- Research Institute
- Other
Companies covered
- Novartis AG
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd.
- Bausch Health Companies, Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2021-2032)
- 1.4.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2021-2026)
- 1.4.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Region (2027-2032)
- 1.5 Key Regions Age-Related Macular Degeneration (AMD) Therapeutics Market Size (2021-2032)
- 1.5.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.4 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (2021-2032)
2 Age-Related Macular Degeneration (AMD) Therapeutics Market by Type
- 2.1 Type Introduction
- 2.1.1 Wet AMD
- 2.1.2 Dry AMD
- 2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Type
- 2.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Overview by Type (2021-2032)
- 2.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecasted by Type (2027-2032)
- 2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions
- 2.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Type (2021-2026)
3 Age-Related Macular Degeneration (AMD) Therapeutics Market by Application
- 3.1 Type Introduction
- 3.1.1 Clinic
- 3.1.2 Hospital
- 3.1.3 Research Institute
- 3.1.4 Other
- 3.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Application
- 3.2.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Overview by Application (2021-2032)
- 3.2.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecasted by Application (2027-2032)
- 3.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Regions
- 3.3.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Age-Related Macular Degeneration (AMD) Therapeutics Industry Trends
- 4.2 Age-Related Macular Degeneration (AMD) Therapeutics Industry Drivers
- 4.3 Age-Related Macular Degeneration (AMD) Therapeutics Industry Opportunities and Challenges
- 4.4 Age-Related Macular Degeneration (AMD) Therapeutics Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Age-Related Macular Degeneration (AMD) Therapeutics Revenue (2021-2026)
- 5.2 Global Age-Related Macular Degeneration (AMD) Therapeutics Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Age-Related Macular Degeneration (AMD) Therapeutics Key Company Headquarters & Area Served
- 5.4 Global Age-Related Macular Degeneration (AMD) Therapeutics Company, Product Type & Application
- 5.5 Global Age-Related Macular Degeneration (AMD) Therapeutics Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Age-Related Macular Degeneration (AMD) Therapeutics Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Age-Related Macular Degeneration (AMD) Therapeutics Players Market Share by Revenue in 2025
- 5.6.3 2025 Age-Related Macular Degeneration (AMD) Therapeutics Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Novartis AG
- 6.1.1 Novartis AG Company Information
- 6.1.2 Novartis AG Business Overview
- 6.1.3 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Novartis AG Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.1.5 Novartis AG Recent Developments
- 6.2 Amgen Inc.
- 6.2.1 Amgen Inc. Company Information
- 6.2.2 Amgen Inc. Business Overview
- 6.2.3 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Amgen Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.2.5 Amgen Inc. Recent Developments
- 6.3 Regeneron Pharmaceuticals Inc.
- 6.3.1 Regeneron Pharmaceuticals Inc. Company Information
- 6.3.2 Regeneron Pharmaceuticals Inc. Business Overview
- 6.3.3 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Regeneron Pharmaceuticals Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.3.5 Regeneron Pharmaceuticals Inc. Recent Developments
- 6.4 F. Hoffmann-La Roche Ltd.
- 6.4.1 F. Hoffmann-La Roche Ltd. Company Information
- 6.4.2 F. Hoffmann-La Roche Ltd. Business Overview
- 6.4.3 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 F. Hoffmann-La Roche Ltd. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.4.5 F. Hoffmann-La Roche Ltd. Recent Developments
- 6.5 Bausch Health Companies, Inc.
- 6.5.1 Bausch Health Companies, Inc. Company Information
- 6.5.2 Bausch Health Companies, Inc. Business Overview
- 6.5.3 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Bausch Health Companies, Inc. Age-Related Macular Degeneration (AMD) Therapeutics Product Portfolio
- 6.5.5 Bausch Health Companies, Inc. Recent Developments
7 North America
- 7.1 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 7.3 North America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 8.3 Europe Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 10.3 South America Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Age-Related Macular Degeneration (AMD) Therapeutics Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst